摘要
目的观察伊立替康联合奈达铂二线治疗小细胞肺癌的疗效以及产生的毒副反应。方法本组所有患者按照以下治疗方法进行化疗:静脉滴注CPT-1165mg/m2,d1、8;静脉滴注NDP80mg/m2,d1。至少化疗2个周期,每个周期为4周。结果 60例均可评价疗效。获得CR9例(15%)、PR35例(58.3%)、SD11例(18.3%)、PD5例(8.3%)。近期客观有效率为73.3%。本组患者的不良反应主要为I/Ⅱ度骨髓抑制及胃肠道反应,Ⅲ/Ⅳ度不良反应发生率极低,本组患者没有出现相关性死亡病例。结论伊立替康联合奈达铂二线治疗小细胞肺癌临床疗效非常显著,毒副反应患者亦可以耐受,值得进一步临床研究。
Objective To observe the efficacy of irinotecan health combined with nedaplatin secondline treatment of small cell lung cancer,and the resulting toxic side effects.Methods All patients in this group following treatment with chemotherapy：intravenous CPT-1165 mg/m2 d1,8,intravenous NDP80 mg/m2,d1.At least two cycles of chemotherapy,each cycle of 4 weeks.Results 60 patients evaluable for efficacy.Get CR 9 patients（15%）,PR 35（58.3%） the SD11 patients（18.3%）,PD 5 cases（8.3%）.The recent objective response rate was 73.3%.The main side effects of this group of patients for I/Ⅱ myelosuppression and gastrointestinal reactions,stage III/IV very low incidence of adverse reactions,this group of patients did not appear related deaths.Conclusion Irinotecan health combined with nedaplatin second-line treatment of small cell lung cancer is very significant toxicity in patients can tolerate,worthy of further clinical studies.
出处
《中国实用医药》
2012年第30期27-28,共2页
China Practical Medicine
关键词
伊立替康
奈达铂
小细胞肺癌
二线治疗
Irinotecan
Nedaplatin
Small cell lung cancer
Second-line treatment
